No Data
Henan Lingrui Pharmaceutical Acquiring 90% Stake in Yingu Pharmaceutical for 704 Million Yuan
Henan Lingrui Pharmaceutical (600285.SH): plans to acquire 90% equity of Silver Valley Pharmaceutical.
Gelonghui, January 27: Henan Lingrui Pharmaceutical (600285.SH) announced that the company intends to purchase 90% of the equity of Yinggu Pharmaceutical Co., Ltd. (hereinafter referred to as "Yinggu Pharmaceutical" or "symbol company") with its own funds, at a transaction price of 703.908 million yuan. Upon completion of this transaction, Yinggu Pharmaceutical will become a subsidiary controlled by the company and included in the consolidated financial statements of the company. After this acquisition, the company or a designated third party has the right to issue an exercise notice during the period from May 1 to May 31, 2027, according to the audited financial statements of the company for 2024 to 2026 under the consolidated scope.
Henan Lingrui Pharmaceutical (600285.SH): The employee stock ownership plan stock sales were completed in 2021.
Gelonghui, January 22丨 Henan Lingrui Pharmaceutical (600285.SH) announced that as of now, the company's stocks held under the 2021 employee stock ownership plan have been entirely sold through the secondary market. During the implementation of the employee stock ownership plan, the company strictly adhered to market trading rules and complied with the regulations of the China Securities Regulatory Commission and the Shanghai Stock Exchange regarding the prohibition of trading stocks during sensitive periods, and there were no circumstances of trading using inside information.
Investors in Henan Lingrui Pharmaceutical (SHSE:600285) Have Seen Strong Returns of 146% Over the Past Five Years
Lingrui Pharmaceutical's Capsule Up for Selection for China's Centralized Traditional Chinese Drug Procurement
Henan Lingrui Pharmaceutical (600285.SH): The company's products are planned to be selected for the national Chinese Patent Medicine procurement alliance's centralized bulk procurement.
On January 2, Gelonghui reported that Henan Lingrui Pharmaceutical (600285.SH) announced its participation in the tendering work for the national Chinese Patent Medicine procurement alliance's centralized bulk purchasing. According to the proposed selection results for the national Chinese Patent Medicine procurement alliance's centralized bulk purchasing (ZCYLM-2024-1) published by the Hubei Medical Insurance Service Platform on December 30, 2024, the company's product, Qiqi Jiangtang capsules, is slated for selection in this centralized bulk purchasing for Chinese Patent Medicine.
Are Robust Financials Driving The Recent Rally In Henan Lingrui Pharmaceutical Co., Ltd.'s (SHSE:600285) Stock?
